%0 Journal Article
%T Effect of the PPAR¦Ã modulation on the reverse pathway of cholesterol
%A M¨®nica Mar¨ªa D¨ªaz L¨®pez
%A Daniel Mauricio Serrano Triana
%A Iv¨¢n Efra¨ªn Mart¨ªnez Forero
%A Dar¨ªo Echeverri Arcila
%J MedUNAB
%D 2006
%I Universidad Aut¨®noma de Bucaramanga
%X Introduction: Nuclear receptor LXR¦Á (liver X receptor alpha) has a beneficial effect on the reverse pathway of cholesterol and reverts some defects in the lipid metabolism that are related with cardiovascular risk. LXR¦Á activity is modulated by agonists of the nuclear receptor PPAR¦Ã  (Peroxisome Proliferator-Activated Receptor gamma), that are used for type 2 Diabetes treatment. Objective: To observe LXR¦Á gene expression and some genes that it regulates, after the treatment with a PPAR¦Ã agonist in the absence of estrogens. Method: 18 New Zealand female rabbits were ophorectomized. Three groups selected themselves randomly. In two groups, were treated with hypercholesterolemic diet during 3 weeks alternating with normal diet for a total of 24 weeks, to one of these groups, administered placebo (group 1, n=6) and to another one rosiglitazone 3 mg/Kg/d¨ªa (group 2, n=6). The third group took like group control with normal diet. The expression of the genes of lxr¦Á, abca1 and il-1¦Â  was determined by means of RT-PCR. Results: An increase in LXR  mRNA expression was observed in liver, without any variationin ABCA1 in artery. A reduction on IL-1¦Â levels in artery after rosiglitazone therapy was observed. Conclusion: PPAR¦Ã activation increases LXR¦Á function in the absence of estrogens. However PPAR¦Ã might execute some beneficial effect on reverse cholesterol pathway in a different route from LXR¦Á/ABCA1 pathway.
%K Reverse pathway of cholesterol
%K LXR¦Á
%K ABCA1
%K IL1¦Â
%K PPAR¦Ã
%K rosiglitazone
%U http://caribdis.unab.edu.co/pls/portal/docs/PAGE/REVISTAMEDUNAB/PPAR%20GAMMA.PDF